Table 1.
Patient characteristics and pharmacological treatment of 10 JIA patients with 11 symptomatic joints
| Characteristics | Number (%) | Median | Range | |
|---|---|---|---|---|
| Sex |
|
|
|
|
| |
Male |
3 (30%) |
|
|
| |
Female |
7 (70%) |
|
|
| Joint |
|
|
|
|
| |
Wrist |
6 (55%) |
|
|
| |
Knee |
3 (27%) |
|
|
| |
Ankle |
2 (18%) |
|
|
| Subgroup |
|
|
|
|
| RF-negative polyarthritis |
|
5 (50%) |
|
|
| Oligoarthritis |
|
2 (20%) |
|
|
| Enthesitis related arthritis |
|
1 (10%) |
|
|
| Psoriasis arthritis |
|
1 (10%) |
|
|
| Systemic |
|
1 (10%) |
|
|
| Age, years |
|
|
14 |
11–18 |
| Disease duration, years |
|
|
4.3 |
0.2–10.2 |
| Drug therapies |
|
|
|
|
| |
Local steroids |
1 (10%) |
|
|
| |
Sulfasalazine |
1 (10%) |
|
|
| |
MTX |
3 (30%) |
|
|
| |
Etanercept |
1 (10%) |
|
|
| |
Golimumab |
1 (10%) |
|
|
| |
MTX + etanercept |
2 (20%) |
|
|
| MTX + golimumab | 1 (10%) |